Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease.

Autor: Liabeuf, Sophie^1,2 (AUTHOR), Hafez, Gaye³ (AUTHOR), Pešić, Vesna⁴ (AUTHOR), Spasovski, Goce⁵ (AUTHOR), Bobot, Mickaël⁶ (AUTHOR), Mačiulaitis, Romaldas^7,8 (AUTHOR), Bumblyte, Inga Arune⁷ (AUTHOR), Ferreira, Ana Carina^9,10 (AUTHOR), Farinha, Ana¹¹ (AUTHOR), Malyszko, Jolanta¹² (AUTHOR), Pépin, Marion^13,14 (AUTHOR), Massy, Ziad A^14,15 (AUTHOR), Unwin, Robert¹⁶ (AUTHOR), Capasso, Giovambattista^17,18 (AUTHOR), Mani, Laila-Yasmin¹⁹ (AUTHOR) Laila.Mani@insel.ch, Target), CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative (AUTHOR)

Publikováno v: Clinical Kidney Journal. Aug2024, Vol. 17 Issue 8, p1-15. 15p.

Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients.

Autor: Weber, RR, McCoy, CE, Ziemniak, JA, Frederickson, ED, Goldberg, LI, Murphy, MB

Publikováno v: British Journal of Clinical Pharmacology; 1988, Vol. 25 Issue 1, p17-21, 5p

Possible alteration of metronidazole metabolism by phenobarbital

Autor: Schentag Jj, Mead Pb, Ziemniak Ja, Mark Gibson

Publikováno v: The New England journal of medicine. 306(24)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e68c47e1d4fb9db8812afa7cc862df8
https://pubmed.ncbi.nlm.nih.gov/7078600

Dispositional characteristics of a tyrosine kinase inhibitor (RG 14620) in rats and rabbits following intravenous administration or dermal application.

Autor: Khetarpal VK; Rhône-Poulenc Rorer Central Research, Collegeville, PA 19426., Markham PM, Ziemniak JA

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 1994 Mar-Apr; Vol. 22 (2), pp. 216-23.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.